A kind of Lactobacillus plantarum HYZQF 1675 iso-7 and its application in preparing calcium supplement products
Through the active ingredients and metabolites of Lactobacillus plantarum HYZQF 1675 iso-7 strain, combined with auxiliary materials, the problem of calcium deficiency in humans is solved, the effective absorption and utilization of calcium is achieved, and bone health is improved.
Patent Information
- Application Number
- CN202411091289.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-09
AI Technical Summary
The problem of human calcium deficiency is serious, leading to health problems such as rickets and osteoporosis. It is difficult for the existing technology to effectively supplement the human calcium elements.
A strain of Lactobacillus plantarum HYZQF 1675 iso-7 was isolated and identified. By preparing its active ingredients and metabolites, it combined with auxiliary materials to make a microbial agent for the provision of ginkgo flavonoids, carotene and aspartic acid in the intestine. Promote the absorption and utilization of calcium.
This strain can regulate the balance of intestinal bacterial flora, continuously provide calcium elements, significantly improve calcium absorption efficiency, improve bone health, and reduce bone loss. It is suitable for calcium supplement drugs and health foods.
Smart Images

Figure CN118620801B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms and relates to Lactobacillus plantarum HYZQF 1675 iso-7 and application thereof in preparing calcium supplement products. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Calcium is a necessity for human life activities and the most abundant inorganic element in the human body. It participates in the entire life process. Studies have shown that calcium is the nutrient that people lack the most. The average daily calcium intake per person is only 400 mg, which is only about 50% of the daily dietary nutrient reference intake standard. With the acceleration of the pace of life and changes in human living and eating habits, calcium deficiency has become a common problem for humans. 99% of the total calcium in the human body is in bones and teeth. Children with calcium deficiency are prone to sweating, crying, and in severe cases, rickets. Calcium deficiency in adults will reduce the strength of the human body and the hardness of bones, and it is easy to have back and leg pain, hunchback, and even pathological fractures in severe cases. Especially for postmenopausal women, the fluctuation of estrogen decreases, which affects the deposition of calcium in the body and the synthesis of collagen. Bone loss will also increase, bone quality begins to decrease sharply, bone brittleness increases, and it is more likely to suffer from osteoporosis. At the same time, calcium deficiency in the body can easily cause high blood pressure and produce neuropathic abnormal excitement (even mental stimulation). In addition, calcium can prevent muscle spasms, blood coagulation, and prevent cancer (colorectal cancer, lung cancer, rectal cancer). Summary of the invention
[0004] The present invention isolated a plant lactobacillus from the pulp of fresh ginkgo fruit in Tianshui City, Gansu Province in September 1994. Studies have shown that the strain can regulate the balance of intestinal flora and promote human digestion and absorption. At the same time, it can sustainably provide the necessary endogenous amount of ginkgo flavonoids, carotene and aspartic acid during the intestinal reproduction and growth process, which can effectively supplement calcium and maintain the health of the body.
[0005] Based on the above research results, the present invention provides the following technical solutions:
[0006] In the first aspect, a Lactobacillus plantarum HYZQF 1675 iso-7, which was deposited in the China Center for Type Culture Collection, abbreviated as CCTCC, on March 22, 2019, with the address: Wuhan University, Wuhan, China, and its biological preservation number is: CCTCC NO: M2019188.
[0007] The strain provided by the invention is identified as Lactobacillus plantarum by 16srRNA method.
[0008] In order to adapt to the industrialized large-scale production of the above-mentioned strain, a culture medium for culturing the above-mentioned strain is also provided, and the culture medium includes an expansion culture medium, a primary seed culture medium, a seed tank culture medium, and a fermentation culture medium.
[0009] Specifically, the expansion culture medium of the strain contains the following ingredients per 1000 mL of water: 13-15 g of glucose, 1.5-2.5 g of isomaltooligosaccharide, 4.5-5.5 g of beef extract powder, 1.5-2.5 g of sodium acetate, 0.45-0.55 mL of Tween-80, and 0.25-0.35 g of potassium dihydrogen phosphate; the pH is 6.9-7.1.
[0010] Specifically, the primary seed culture medium of the strain contains the following ingredients per 1000 mL of water: 7-9 g of isomaltooligosaccharide, 3.5-4.5 g of peptone, 2.5-3.5 g of beef extract powder, 1.3-1.7 g of serine, 0.55-0.65 g of sodium acetate, 1.5-2.5 g of threonine, and 0.5-1.5 mL of Tween-80.
[0011] Specifically, the seed tank culture medium of the strain contains the following components in parts by weight: 1.3-1.7 parts of isomaltooligosaccharide, 0.8-1.0 parts of casein peptone, 0.25-0.35 parts of dipotassium hydrogen phosphate, 0.45-0.55 parts of serine, 0.08-0.12 parts of sodium acetate, 0.7-0.9 parts of arginine, 0.7-0.9 parts of glutamic acid, 0.08-0.12 parts of Tween-80, 0.08-0.12 parts of polyether defoamer, and 92.0-97.0 parts of water.
[0012] Specifically, the fermentation medium of the strain contains the following ingredients in parts by weight: 0.8-1.2 parts of isomaltooligosaccharide, 0.25-0.35 parts of isomaltulose, 0.45-0.55 parts of glucose, 0.8-1.0 parts of casein peptone, 0.8-1.2 parts of corn oligopeptides, 0.8-1.2 parts of yeast extract powder, 0.7-0.9 parts of sodium acetate, 0.25-0.35 parts of Tween-80, 0.45-0.55 parts of leucine, 0.35-0.45 parts of proline, 0.6-0.8 parts of dipotassium hydrogen phosphate, 0.08-0.12 parts of polyether defoamer, and 90.0-95.0 parts of tap water.
[0013] In a second aspect, a microbial agent comprises an active ingredient, wherein the active ingredient comprises the above-mentioned Lactobacillus plantarum HYZQF 1675 iso-7 or its inactivated bacteria, fermentation broth, and metabolites.
[0014] Specifically, the active ingredient is the metabolite of Lactobacillus plantarum HYZQF 1675 iso-7.
[0015] Specifically, the invention further comprises auxiliary materials, wherein the auxiliary materials comprise one or more of maltodextrin, anhydrous glucose, trehalose and calcium gluconate. The mass ratio of the active ingredient to maltodextrin, anhydrous glucose, trehalose and calcium gluconate is 1000:250-350:1400-1600:14-16:55-65.
[0016] Specifically, the microbial agent is a freeze-dried powder. The preparation process is: adding the active ingredient and the auxiliary material to sterile physiological saline, mixing evenly, and freeze-drying. More specifically, the moisture content of the freeze-dried powder is 3.5-4.5%.
[0017] In a third aspect, a use of the above-mentioned Lactobacillus plantarum HYZQF 1675 iso-7 or microbial agent in the preparation of a calcium supplement product.
[0018] The calcium supplement product of the present invention can be a medicine for calcium supplementation or a food for calcium supplementation; the food is a health food.
[0019] Specifically, the calcium supplement product is administered to humans or non-human mammals, such as rats, mice, rabbits, dogs, etc.
[0020] In a fourth aspect, a use of the above-mentioned Lactobacillus plantarum HYZQF 1675 iso-7 or microbial agent in the preparation of a drug for enhancing beneficial ingredients in the intestine, wherein the beneficial ingredients are one or more of ginkgo flavonoids, carotene, and aspartic acid.
[0021] Specifically, the drug for increasing beneficial components in the intestinal tract is administered to humans or non-human mammals, such as rats, mice, rabbits, dogs, and the like.
[0022] The beneficial effects of the present invention are:
[0023] The plant lactobacillus HYZQF 1675 iso-7 provided by the present invention is a probiotic strain, which has the effect of regulating the balance of intestinal flora and promoting human digestion and absorption, and also has the effect of conditioning and effectively supplementing the calcium element required by the human body. Daily administration of 7 billion strains of the present invention and 110 mg of metabolites can sustainably provide the endogenous necessary amount of ginkgo flavonoids, carotene and aspartic acid during the intestinal reproduction and growth process. It can effectively supplement calcium and maintain the health of the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0025] Figure 1 This is an ultra-high performance liquid chromatogram of the detection of mouse feces in Example 1 of the present invention. DETAILED DESCRIPTION
[0026] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0027] Example
[0028] The strain used in this example is Lactobacillus plantarum HYZQF 1675 iso-7 ( Lactobacillus plantarum HYZQF 1675 iso-7), was deposited in China Center for Type Culture Collection (CCTCC) on March 22, 2019, at Wuhan University, Wuhan, China, and its biological deposit number is CCTCC NO: M2019188.
[0029] Bacterial strain culture: Expansion culture of bacterial strains preserved in -80℃ refrigerator.
[0030] Preparation of culture medium: 14 g glucose, 2 g isomaltooligosaccharide, 5 g beef extract powder, 2 g sodium acetate, 0.5 mL Tween-80, 0.3 g potassium dihydrogen phosphate, 1000 mL tap water, pH adjusted to 7.0 (alkaline solution adjustment).
[0031] Operation: Add the glucose and other raw materials in the above formula into 1000mL of water in the formula without any particular order, stir for 10 minutes to dissolve, then divide into test tubes, 5mL per test tube, seal with kraft paper stopper, place in a medical sterilizer and sterilize at 0.11MPa for 20 minutes, and the culture medium is ready.
[0032] Inoculation: Under sterile conditions (clean bench), open the -80℃ low-temperature refrigerator to store the frozen tube of bacteria, dissolve it at room temperature, then take one sterilized test tube culture medium, add 0.5mL of the dissolved bacterial solution into the test tube, seal the tube mouth with kraft paper, shake it gently by hand, put it in a constant temperature incubator at 37℃ and culture it for 18 hours. This is called expansion culture medium.
[0033] Primary seed culture formula: 8 g isomaltooligosaccharide, 4 g peptone, 3 g beef extract powder, 1.5 g serine, 0.6 g sodium acetate, 2 g threonine, 1 mL Tween-80, and 1000 mL tap water.
[0034] Operation: Add the above raw materials into 1000mL of tap water without any distinction, start the blender, and stir for 10 minutes to dissolve them all. This is called the primary seed culture solution.
[0035] Add the stirred and dissolved first-grade seed culture solution into the conical flask according to the dosage, then wrap the bottle mouth with 6 layers of gauze and a layer of kraft paper, and put it into the sterilizer for sterilization. Before sterilization, first open the exhaust valve on the sterilizer and close it when a small amount of steam is discharged. When the pressure on the sterilizer reaches 0.05MPa, open the exhaust valve on the sterilizer to exhaust for 6-8min, then close the exhaust valve and continue heating. When the steam pressure in the sterilizer reaches 0.11MPa, start timing. The sterilization time is 20min. After completion, leave the heat source and let it cool down naturally. When the sterilizer is When the pressure gauge on the sterilizer returns to zero, open the sterilizer, take out the sterilized culture medium and put it into the clean bench to cool naturally. When the temperature drops to 37°C, transfer the above cultured expanded bacterial culture liquid to the triangular flask containing sterilized culture liquid. The inoculation amount is 0.5%, that is, 100mL of primary seed culture liquid and 0.5mL of expanded bacterial liquid. After completion, seal the bottle mouth with the original gauze and kraft paper, shake it slightly by hand to mix the accessed bacteria and culture liquid evenly, and then place it in a constant temperature box and culture it at 37°C for 20 hours. This is called the primary bacterial culture liquid.
[0036] Sterilization of fermentation equipment, pipelines and sterile filtration systems:
[0037] First, open the valves of all inlet and outlet pipelines and sterile air pipelines, pass 0.13MPa steam, allow the steam to connect with the pipeline valve and discharge a small amount of steam, ventilate for 40 minutes, and then close the valves of all inlet and outlet pipelines for standby use.
[0038] Sterilization of empty seed tanks and fermentation tanks:
[0039] Close all valves, open the drain valve at the bottom of the tank and the drain valve in the tank interlayer, open the direct steam valve to introduce 0.13MPa steam into the pipe, start timing when the temperature in the tank reaches 121℃, the sterilization time is 40min, then close the drain valve at the bottom of the tank and the drain valve in the interlayer, and the temperature in the tank will naturally drop to 37℃ for standby use.
[0040] Seed pot culture:
[0041] Formula: 1.5% isomaltooligosaccharide, 0.9% casein peptone, 0.3% dipotassium hydrogen phosphate, 0.5% serine, 0.1% sodium acetate, 0.8% arginine, 0.8% glutamic acid, 0.1% Tween-80, 0.1% polyether defoamer, and 94.9% tap water.
[0042] Specific operation: First, pour the tap water used in the formula into the sterilized seed tank, start the mixer, add the raw materials required in the formula respectively (the order of addition is not important), then stir continuously and pass steam for heating. First, use the steam in the tank interlayer to heat to 95°C, then switch to direct steam heating. When the temperature in the tank reaches 121°C, maintain it for 20 minutes to achieve the sterilization effect, then turn off the steam, and start cooling through the tap water in the tank interlayer. When the temperature in the tank reaches 37°C, it is ready for use. This is called seed culture medium. Then inoculate the above-cultured first-level bacterial culture solution into the seed tank under sterile conditions. The inoculation amount is 3% of the culture medium in the tank. 100 kg of seed tank culture medium can be inoculated with 3 kg of first-level bacterial solution. Then cover the inoculation cap on the tank and start stirring and culturing. The culture conditions are: temperature 37°C, stirring speed 120r / min, tank pressure 0.05MPa, and culture time 12h to meet the requirements. If the tank body is lowered, sterile air can be introduced to maintain the tank pressure. If the tank pressure is too high, the air release valve on the tank top can be used to adjust it. This is called seed tank culture.
[0043] Fermentation
[0044] Formula: 1% isomaltooligosaccharide, 0.3% isomaltulose, 0.5% glucose, 0.9% casein peptone, 1% corn oligopeptide, 1% yeast extract powder, 0.8% sodium acetate, 0.2% Tween-80, 0.5% leucine, 0.4% proline, 0.7% dipotassium hydrogen phosphate, 0.1% polyether defoamer, and 92.6% tap water.
[0045] Specific operation: First, add the tap water used in the formula into the sterilized fermentation tank, start the mixer, add the raw materials used in the formula into the fermentation tank (the order of addition is not important), and then pass steam for heating. First, use the interlayer steam to heat to 95°C, and then switch to direct steam heating. When the temperature in the tank reaches 121°C, start timing, and keep it for 30 minutes to achieve the sterilization effect, and then cool it down with the tap water in the interlayer. When the temperature in the tank drops to 37°C, start to inoculate the strains. Before inoculation, first increase the tank pressure of the seed tank to 0.1MPa, and keep the tank pressure of the fermentation tank at 0.05MPa, then open the inoculation pipeline valve, and transport the seeds cultured in the seed tank to the fermentation tank by pressure difference, and then close the inoculation channel valve.
[0046] The inoculation amount is 3 kg of bacteria cultured in the seed tank for every 100 kg of culture medium in the fermentation tank. The culture conditions are: culture temperature 37°C, stirring speed 140r / min, tank pressure maintained at 0.05MPa, and the acid and alkali automatic control system is used to maintain the pH value at 5.5 during the fermentation process. If the tank pressure drops, sterile air can be introduced to maintain the tank pressure until the fermentation is completed. The total fermentation time is 30 hours, and then the temperature is lowered to 20°C. This is the fermentation broth. 2% trehalose is added to the fermentation broth and kept at 120°C for 6 seconds for UHT inactivation treatment.
[0047] Fermentation broth centrifugation
[0048] The fermentation liquid is pumped into a storage tank for centrifugation. Operation: Start the centrifuge, adjust the speed to 10000r / min, centrifuge at a feed rate of 4kg / min, collect the wet bacterial sludge metabolites after centrifugation, and freeze-dry the collected wet bacterial sludge metabolites.
[0049] Freeze-drying of bacterial sludge metabolites
[0050] Preparation of bacterial suspension: Take 1000 g of inactivated wet bacterial sludge metabolites, add 4000 mL of sterile saline, 300 g of maltodextrin, 1500 g of anhydrous glucose, 15 g of trehalose, and 60 g of calcium gluconate.
[0051] Operation: First, take 2500mL of sterile saline in the formula, add maltodextrin and stir to dissolve, then add 1000g of inactivated wet bacterial sludge metabolites, and then add the remaining sterile saline and anhydrous glucose and auxiliary materials in the formula and stir well, which is called a suspension. The suspension is freeze-dried and the moisture content is finally controlled to 4%, which becomes a freeze-dried powder of inactivated bacterial metabolites.
[0052] Metabolomics analysis
[0053] Metabolomics analysis of mouse feces was performed using ultra-performance liquid chromatography-tandem mass spectrometry.
[0054] Experimental plan: The mice were divided into a control group and an experimental group. The control group was fed normally, while the experimental group was added with the above-mentioned freeze-dried powder of inactivated bacterial metabolites (a probiotic product containing 700 million inactivated bacterial cells and 110 mg of metabolites) in their food. After ten days of feeding, fecal samples of the mice in the control group and the experimental group were placed in 400 μL of extraction solution (acetonitrile: methanol = 1:1), vortexed for 30 seconds, and extracted with low-temperature ultrasound for 30 minutes (5°C, 40 KHz), allowed to stand at -20°C for 30 minutes, placed in a 4°C centrifuge, and centrifuged at 13000 r / min for 15 minutes. The supernatant was taken, dried with nitrogen, and re-dissolved with 120 μL of re-solution (acetonitrile: water = 1:1). After low-temperature ultrasonic extraction for 5 minutes (5°C, 40 KHz), the sample was placed in a 4°C centrifuge, and centrifuged at 13000 r / min for 5 minutes. An appropriate amount of supernatant was taken for analysis. 10μL of sample supernatant was separated by BEH C18 column (100mm ×2.1mm id, 1.8µm) and then entered mass spectrometry detection. The separation flow rate was 0.40mL / min and the column temperature was 40℃. After completion, the LC-MS raw data was transferred to the computer for processing and analysis. The chromatogram is shown in Figure 1 The MS mass spectrum information was matched with the public database, and the main metabolite information was obtained as shown in Table 1.
[0055] Table 1 Main metabolomics analysis of probiotic-fed mice
[0056]
[0057]
[0058] Table 1 shows that feeding Lactobacillus plantarum HYZQF 1675 iso-7 can significantly increase the content of ginkgo flavonoids, carotene and aspartic acid in mouse feces. This is due to the increase in the content of ginkgo flavonoids, carotene and aspartic acid in the mouse intestine. This shows that Lactobacillus plantarum HYZQF 1675 iso-7 can continuously provide the endogenous necessary amount of ginkgo flavonoids, carotene and aspartic acid in the mouse intestine.
[0059] Among them, ginkgo flavonoids, carotene and aspartic acid can stimulate the native flora in the intestine, thereby promoting calcium absorption, and aspartic acid can inhibit the growth of calcium oxalate, thereby reducing calcium loss in the body.
[0060] The freeze-dried powder of the inactivated bacterial metabolites prepared above is used for calcium supplementation
[0061] In this application trial, the subjects were calcium-deficient people aged 6-70 years old from two communities in Jinan City. As of June 2019, a total of 300 people were recruited to participate in the experiment. All of the above-mentioned persons signed a written informed consent form. If the participant was unable to sign, an agent (usually a family member) would sign it.
[0062] The inactivated bacteria metabolite freeze-dried powder prepared as above was taken by the people who needed calcium supplementation. The conditions of the people and the inactivated bacteria metabolite freeze-dried powder taken in the application test are shown in Table 2.
[0063] Table 2 Consumption of freeze-dried powder of killed bacterial metabolites by personnel
[0064]
[0065]
[0066] In the children's group, 50 people started to collect the results after taking the medicine for 8 days. After taking it for 8 days, 13 people felt that their teeth were loose, their tooth decay was frequent, they sweated a lot when they slept, they were easily irritable, irritable, crying and restless, their mood swings were large, and they had difficulty concentrating. After taking it for 16 days, 22 people felt that their teeth were loose, their tooth decay was frequent, they sweated a lot when they slept, they were easily irritable, irritable, crying and restless, their mood swings were large, and they had difficulty concentrating. After taking it for 24 days, 38 people felt that their teeth were loose, their tooth decay was frequent, they sweated a lot when they slept, they were easily irritable, irritable, crying and restless, their mood swings were large, and they had difficulty concentrating. After taking it for 30 days, 46 people had completely improved their teeth, their tooth decay was frequent, they sweated a lot when they slept, they were easily irritable, irritable, crying and restless, their mood swings were large, and they had difficulty concentrating. A total of 4 people failed to improve after taking Lactobacillus plantarum.
[0067] In the adolescent group, 50 people started to collect the results after taking it for 8 days. After taking it for 8 days, 12 people felt that their growing pains, leg weakness, cramps, fatigue, irritability, lack of concentration, partial eclipse, anorexia, easy allergies, and easy colds improved. After taking it for 16 days, 22 people had obvious improvement in their growing pains, leg weakness, cramps, fatigue, irritability, lack of concentration, partial eclipse, anorexia, easy allergies, and easy colds. After taking it for 24 days, 35 people had extremely obvious improvement in their growing pains, leg weakness, cramps, fatigue, irritability, lack of concentration, partial eclipse, anorexia, easy allergies, and easy colds. After taking it for 30 days, 45 people had completely improved their growing pains, leg weakness, cramps, fatigue, irritability, lack of concentration, partial eclipse, anorexia, easy allergies, and easy colds. A total of 5 people failed to improve after taking Lactobacillus plantarum.
[0068] In the elderly group, 50 people started to collect the results after taking the medicine for 8 days. After taking it for 8 days, 11 people felt that osteoporosis, height reduction, leg cramps, tooth loss, spinal deformity, insomnia and dreaminess improved. After taking it for 16 days, 19 people felt that osteoporosis, height reduction, leg cramps, tooth loss, spinal deformity, insomnia and dreaminess improved significantly. After taking it for 24 days, 35 people had osteoporosis, height reduction, leg cramps, tooth loss, spinal deformity, insomnia and dreaminess improved extremely significantly. After taking it for 30 days, 47 people had osteoporosis, height reduction, leg cramps, tooth loss, spinal deformity, insomnia and dreaminess completely improved. After taking it for 100 days, blood pressure stabilized within the normal range. A total of 3 people did not improve after taking Lactobacillus plantarum.
[0069] The bacterial sequences identified by 16srRNA method are as follows:
[0070]
[0071] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A Lactobacillus plantarum ( Lactobacillus plantarum )HYZQF 1675 Iso-7, Its characteristics are: The Lactobacillus plantarum HYZQF 1675 iso-7 is preserved in China Center for Type Culture Collection, and the biological preservation number is: CCTCC NO: M2019188.
2. A microbial agent comprising an active ingredient, Its characteristics are: The active ingredient comprises the Lactobacillus plantarum HYZQF 1675 iso-7 or its fermentation liquid according to claim 1.
3. The microbial agent according to claim 2, Its characteristics are: The active ingredient is the fermentation liquid of the Lactobacillus plantarum HYZQF1675 iso-7.
4. The microbial agent according to claim 2, Its characteristics are: The invention also comprises auxiliary materials, which include one or more of maltodextrin, anhydrous glucose, trehalose and calcium gluconate.
5. The microbial agent according to claim 2, Its characteristics are: The microbial agent is freeze-dried powder.
6. Use of the Lactobacillus plantarum HYZQF 1675 iso-7 according to claim 1 or the microbial agent according to any one of claims 2 to 5 in the preparation of a calcium supplement product.
7. The use according to claim 6, Its characteristics are: The calcium supplement product is administered to humans or non-human mammals.
8. Use of the plant lactobacillus HYZQF 1675 iso-7 according to claim 1 or the microbial agent according to any one of claims 2 to 5 in the preparation of a medicament for enhancing beneficial ingredients in the intestinal tract, wherein the beneficial ingredients are one or more of ginkgo flavonoids, carotene, and aspartic acid.
9. The use according to claim 8, Its characteristics are: The subject of administration of the drug for increasing beneficial components in the intestinal tract is a human or a non-human mammal.
Citation Information
Patent Citations
Lactobacillus plantarum and application thereof
CN112877262A
Lactobacillus plantarum 10A-2 for improving anxiety and depression and application of lactobacillus plantarum 10A-2
CN117327631A
Nano-sized kimchi lactic acid bacteria
US20160074443A1
